Showing results (101-110 of 293) with videos related to
Sort By:
Pageof 30
BMC Medical Imaging|April 28, 2017
A comparison of pediatric and adult CT organ dose estimation methodsYiming Gao, Brian Quinn, Usman Mahmood, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|June 5, 2014
Impact of pre-operative positron emission tomography in gallbladder cancerUniverse Leung, Neeta Pandit-Taskar, Carlos U Corvera, et al.Journal of Hematology & Oncology|November 12, 2022
Phase 1 study of intraventricular <sup>131</sup>I-omburtamab targeting B7H3 (CD276)-expressing CNS malignanciesKim Kramer, Neeta Pandit-Taskar, Brian H Kushner, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 24, 2013
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancerMary L Gemignani, Sujata Patil, Venkatraman E Seshan, et al.Radiology|August 11, 2010
Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survivalEvis Sala, Masako Kataoka, Neeta Pandit-Taskar, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I studyBrian H Kushner, Kim Kramer, Shakeel Modak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the UnknownsGeorge Sgouros, Yuni K Dewaraja, Freddy Escorcia, et al.Pageof 30